Arkolith/Insider Trading/AKYA/Form 4

McKelligon Brian

President and CEO, DirectorAkoya Biosciences, Inc. (AKYA) · full profile →Form 4 · filed Jun 7, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$15K
Net Open-Market Flow
-$15K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 6, 2024Option exercise(M)8K$0.30$2K232K
Jun 6, 2024Sell(S)8K$2.01$15K225K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 6, 2024Option exercise(M)8K—$0283K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-069821) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML